Please login first

Noncoding RNA World: From Mechanism to Therapy

21/07/2021 - 23/07/2021, VIRTUAL, International
Abstract Submission
16th April 2021
Acceptance Notification
14th May 2021
Registration Deadline
14th July 2021
Covering Author Registration
25th June 2021

Noncoding RNA, Mechanisms, Bioinformatics, Therapeutics, Biotechnology
Add this conference to bookmark
Conference Registration Submit Abstract Contact Us

Abstract Submission - Deadline Extension

Due to the many requests from attendees, the deadline to submit an abstract has been extended until 16 April 2021, so do not miss this chance to submit your work and be in with a chance of winning our Best Poster (CHF 400.-) or Best Oral Presentation Award (CHF 500.-). You will also be granted a 50% discount to publish a full manuscript in our sponsoring journal non-coding RNA.

Welcome from the Chairs

Dear Colleagues,

It is a great pleasure to announce the upcoming conference “Noncoding RNA World: from Mechanism to Therapy”, to take place virtually (originally planned in Basel (Switzerland)) on 21-23 July 2021.

Vast numbers of new and mysterious ncRNAs continue to be discovered across the tree of life. Although many key questions remain to be answered, nevertheless there are grounds for great optimism for the relevance of ncRNAs to biology and medicine. Powerful new tools are being refined to detect and manipulate ncRNAs with confidence and accuracy, including chemical structure probing, spatially-resolved sequencing, and of course CRISPR-based technologies. At the same time, rapid strides are being made in translating these findings to the clinic, not least thanks to oligonucleotide drugs.

This meeting aims to bring together the community to discuss these latest advances, with sessions on molecular mechanisms, bioinformatics, biotechnology, disease and therapeutics chaired by leading researchers from across the globe.

In the interests of safety given the present COVID-19 situation, we have decided to bring the conference to a fully online format. The conference will proceed on the same dates with the same fantastic Speakers.

Importantly, we aim to select a high number of oral presentations from early-stage researchers, from their submitted abstracts.

We look forward to seeing you this July online!

Rory Johnson and Ling-Ling Chen
ncRNA2021 Chairs
Sponsored by:
Conference Secretariat
Pablo Velázquez
Charlotte Gardini

Conference Chairs

Prof. Dr. Rory Johnson

National Centre of Competence in Research (NCCR ) “RNA & Disease”, University of Bern

Prof. Dr. Ling-Ling Chen

Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences

Keynote Speakers

Dr. Piero Carninci

RIKEN Center for Integrative Medical Sciences, Deputy Director

DETAILS

Born and educated in Italy. He moved to RIKEN Japan in 1995 and got tenure in 1997. He has developed technologies for transcriptome analysis, the cap-trapper and the CAGE, which have been broadly used in the FANTOM and allowed identifying ncRNAs as the major output of the mammalian genome and providing comprehensive maps of the mammalian promoters. He is the Deputy Director of the RIKEN Center for Integrative Medical Sciences since 2018 and holds a position at Human Technopole (Milan) in 2019.

Bio
Born and educated in Italy. He moved to RIKEN Japan in 1995 and got tenure in 1997. He has developed technologies for transcriptome analysis, the cap-trapper and the CAGE, which have been broadly used in the FANTOM and allowed identifying ncRNAs as the major output of the mammalian genome and providing comprehensive maps of the mammalian promoters. He is the Deputy Director of the RIKEN Center for Integrative Medical Sciences since 2018 and holds a position at Human Technopole (Milan) in 2019.

Prof. Dr. Narry Kim

Center for RNA Research, Institute for Basic Science, Korea,
School of Biological Sciences, Seoul National University, Korea

DETAILS

Narry Kim is a Professor in the School of Biological Sciences at Seoul National University and a founding director of RNA Research Center at Institute for Basic Science. She received her Ph.D. in 1998 from the University of Oxford where she studied lentiviruses and gene delivery. With keen interest in RNA biology, she joined the Gideon Dreyfuss lab at the University of Pennsylvania and researched the role of the exon junction complex in mRNA surveillance. Her current research group investigates how genes are regulated at the RNA level, with particular interests in microRNA, mRNA, and viral RNA. She is a recipient of the L’Oreal-UNESCO Women in Science Award, Hoam Prize, and Asan Prize, and a member of KAS, NAS and EMBO.

Talk
Narry Kim is a Professor in the School of Biological Sciences at Seoul National University and a founding director of RNA Research Center at Institute for Basic Science. She received her Ph.D. in 1998 from the University of Oxford where she studied lentiviruses and gene delivery. With keen interest in RNA biology, she joined the Gideon Dreyfuss lab at the University of Pennsylvania and researched the role of the exon junction complex in mRNA surveillance. Her current research group investigates how genes are regulated at the RNA level, with particular interests in microRNA, mRNA, and viral RNA. She is a recipient of the L’Oreal-UNESCO Women in Science Award, Hoam Prize, and Asan Prize, and a member of KAS, NAS and EMBO.

Invited Speakers

Prof. Dr. Janusz M. Bujicki

Laboratory of Bioinformatics and Protein Engineering, International Institute of Molecular and Cell Biology, Poland Website

DETAILS

Prof. Janusz M. Bujnicki’s research combines bioinformatics, structural biology, and synthetic biology, and currently focuses on RNA structure determination and design. His scientific achievements include the development of methods for computational modeling of protein and RNA 3D structures, discovery and characterization of enzymes involved in RNA metabolism, engineering of proteins with new functions, and recently he participated in the determination of the SARS-CoV-2 virus RNA structure.

Bio
Prof. Janusz M. Bujnicki’s research combines bioinformatics, structural biology, and synthetic biology, and currently focuses on RNA structure determination and design. His scientific achievements include the development of methods for computational modeling of protein and RNA 3D structures, discovery and characterization of enzymes involved in RNA metabolism, engineering of proteins with new functions, and recently he participated in the determination of the SARS-CoV-2 virus RNA structure.

Prof. Dr. Sven Diederichs

Division of Cancer Research, Dept. of Thoracic Surgery, University of Freiburg, Freiburg, Germany Website,
Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany Website

DETAILS

Sven Diederichs is a full professor for "Cancer Research" at the University of Freiburg and also leads the division “RNA Biology & Cancer” at the German Cancer Research Center (DKFZ) in Heidelberg. His research focuses on the function and molecular mechanisms of long non-coding RNAs (Hepatology 2018, Nat Commun 2020), RNA-dependent protein complexes (Mol Cell 2019, Nat Protoc 2020) and novel types of mutations (Nat Commun 2019, Nat Cell Biol 2020) in human cancer.

Bio
Sven Diederichs is a full professor for "Cancer Research" at the University of Freiburg and also leads the division “RNA Biology & Cancer” at the German Cancer Research Center (DKFZ) in Heidelberg. His research focuses on the function and molecular mechanisms of long non-coding RNAs (Hepatology 2018, Nat Commun 2020), RNA-dependent protein complexes (Mol Cell 2019, Nat Protoc 2020) and novel types of mutations (Nat Commun 2019, Nat Cell Biol 2020) in human cancer.

Prof. Dr. Shinichi Nakagawa

RNA Biology Laboratory, Faculty of Pharmaceutical Sciences, Hokkaido University Website

Dr. Aiming Ren

Life Sciences Institute, Zhejiang University, China Website

DETAILS

Dr. Aiming Ren is a principal investigator in Life Sciences Institute at Zhejiang University (China). She received her PhD degree in structural biology from Shanghai Institute of Organic Chemistry, Chinese Academy of Science in 2010. Then she joined Prof. Dinshaw Patel’s Lab in Memorial Sloan-kettering Cancer Center (MSKCC) in New York and worked as research associate. In 2016, she went back to China and established her own lab in Zhejiang University

Bio
Dr. Aiming Ren is a principal investigator in Life Sciences Institute at Zhejiang University (China). She received her PhD degree in structural biology from Shanghai Institute of Organic Chemistry, Chinese Academy of Science in 2010. Then she joined Prof. Dinshaw Patel’s Lab in Memorial Sloan-kettering Cancer Center (MSKCC) in New York and worked as research associate. In 2016, she went back to China and established her own lab in Zhejiang University

Dr. Xiaohua Shen

Tsinghua University, China Website

DETAILS

Xiaohua Shen is a Cheung Kong Scholar and associate professor in the School of Medicine at Tsinghua University. Her major research interest is to understand how the non-coding portions of the genome influence chromatin structure, gene expression, and stem-cell fate in development. In the past years, the Shen lab has rigorously investigated novel aspects of ncRNAs, genomic repeats, and RNA-binding proteins in the regulation of transcription, chromatin and genome organization. Her work facilitates the functional inference of ncRNA genes, and brings about a paradigm shift in our understanding of RNA in gene regulation and cell-fate determination.

Talk
Xiaohua Shen is a Cheung Kong Scholar and associate professor in the School of Medicine at Tsinghua University. Her major research interest is to understand how the non-coding portions of the genome influence chromatin structure, gene expression, and stem-cell fate in development. In the past years, the Shen lab has rigorously investigated novel aspects of ncRNAs, genomic repeats, and RNA-binding proteins in the regulation of transcription, chromatin and genome organization. Her work facilitates the functional inference of ncRNA genes, and brings about a paradigm shift in our understanding of RNA in gene regulation and cell-fate determination.

Prof. Dr. Thomas Thum

Institute of Molecular and Translational Therapeutic Strategies, Medizinische Hochschule Hannover (MHH), Germany Website

DETAILS

Thomas Thum is an internist and cardiologist. He received his PhD at the Imperial College, London. He is a full professor and director of the Institute of Molecular and Translational Therapeutic Strategies at Hannover Medical School (MHH) and since January 2021 director of the Fraunhofer Institute for Toxicology and Experimental Medicine. He (co-) authored 400 publications and is a distinguished reviewer, board member, patent holder, and founder.

Bio
Thomas Thum is an internist and cardiologist. He received his PhD at the Imperial College, London. He is a full professor and director of the Institute of Molecular and Translational Therapeutic Strategies at Hannover Medical School (MHH) and since January 2021 director of the Fraunhofer Institute for Toxicology and Experimental Medicine. He (co-) authored 400 publications and is a distinguished reviewer, board member, patent holder, and founder.

Dr. Igor Ulitsky

Weizmann Insitute of Science Website

DETAILS

Dr. Igor Ulitsky completed his PhD in Computational Biology at Tel Aviv University (Israel) in 2009. After completing his PhD, he was a postdoctoral fellow at the Whitehead Institute for Biomedical Research in Cambridge, MA in the US, in the lab of Prof. David Bartel. In 2013, he returned to Israel as a Senior Scientist (Assistant Professor) at the Weizmann Institute of Science, leading a group focused on the functions and modes of action of long noncoding RNAs (lncRNAs) in mammalian cells.

Bio
Dr. Igor Ulitsky completed his PhD in Computational Biology at Tel Aviv University (Israel) in 2009. After completing his PhD, he was a postdoctoral fellow at the Whitehead Institute for Biomedical Research in Cambridge, MA in the US, in the lab of Prof. David Bartel. In 2013, he returned to Israel as a Senior Scientist (Assistant Professor) at the Weizmann Institute of Science, leading a group focused on the functions and modes of action of long noncoding RNAs (lncRNAs) in mammalian cells.

Conference Committee

Prof. Dr. Xichen Bao

Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, China Website

DETAILS

Dr. Xichen Bao is Principal Investigator (PI) in Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH). He received his Ph.D degree in Biochemistry and Molecular Biology from University of Science and Technology of China, Hefei, in 2011. Afterwards, he joined GIBH as research assistant working on lncRNAs in somatic cell reprogramming, and was promoted as PI in 2018. Dr. Bao’s major interest is to understand how ncRNAs and their associated proteins regulate cell fate transitions in physiological or pathological processes using in vitro and in vivo models.

Bio
Dr. Xichen Bao is Principal Investigator (PI) in Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH). He received his Ph.D degree in Biochemistry and Molecular Biology from University of Science and Technology of China, Hefei, in 2011. Afterwards, he joined GIBH as research assistant working on lncRNAs in somatic cell reprogramming, and was promoted as PI in 2018. Dr. Bao’s major interest is to understand how ncRNAs and their associated proteins regulate cell fate transitions in physiological or pathological processes using in vitro and in vivo models.

Prof. Dr. Assaf Bester

Department of Biology, Technion - Israel Institute of Technology, Israel

DETAILS

Assaf Bester is an assistant professor at the Technion - Israel Institute of Technology, Faculty of Biology, Haifa, Israel. Assaf's research focuses on understanding the complexity of gene regulation and its role in human diseases. Assaf completed his Ph.D. at the Hebrew University of Jerusalem, Israel, in 2012 and was ‎invited as an EMBO Fellow to Harvard Medical School. The ‎research in the Bester lab focuses on understanding the role of the non-coding genome in hematopoiesis and cancer.

Bio
Assaf Bester is an assistant professor at the Technion - Israel Institute of Technology, Faculty of Biology, Haifa, Israel. Assaf's research focuses on understanding the complexity of gene regulation and its role in human diseases. Assaf completed his Ph.D. at the Hebrew University of Jerusalem, Israel, in 2012 and was ‎invited as an EMBO Fellow to Harvard Medical School. The ‎research in the Bester lab focuses on understanding the role of the non-coding genome in hematopoiesis and cancer.

Dr. Valerio Costa

CNR Researcher - Unit of Molecular and Computational Biology, Institute of Genetics and Biophysics, Italy

DETAILS

CURRENT POSITIONS Teaching Assistant in Molecular Biology, Faculty of Science and Technology, “Parthenope” University. Qualification as Associate Professor in “Molecular Biology” and in “General and Clinical Pathology”. EDUCATION PhD in Metabolism and Ageing, Faculty of Medicine, University of Campania Luigi Vanvitelli, Department of Aging and Gerontology. Degree in Biotechnology (Pharmaceutical course), University “Federico II” of Naples, Italy. RESEARCH TOPICS 1) The role of long non-coding RNAs in the tumorigenesis of thyroid carcinomas and in drug resistance of BRAF-mutated tumors. 2) The metabolic rewiring of tumor cells and the contribution of somatic alterations - in known cancer driver genes - to this process.

Bio
CURRENT POSITIONS Teaching Assistant in Molecular Biology, Faculty of Science and Technology, “Parthenope” University. Qualification as Associate Professor in “Molecular Biology” and in “General and Clinical Pathology”. EDUCATION PhD in Metabolism and Ageing, Faculty of Medicine, University of Campania Luigi Vanvitelli, Department of Aging and Gerontology. Degree in Biotechnology (Pharmaceutical course), University “Federico II” of Naples, Italy. RESEARCH TOPICS 1) The role of long non-coding RNAs in the tumorigenesis of thyroid carcinomas and in drug resistance of BRAF-mutated tumors. 2) The metabolic rewiring of tumor cells and the contribution of somatic alterations - in known cancer driver genes - to this process.

Dr. Phillip Grote

Cardio-pulmonary Development, Institute of Cardiovascular Regeneration, Centre for Molecular Medicine, Goethe University, Germany Website

DETAILS

Phillip Grote is principal investigator at the Institute of Cardiovascular Regeneration of the Goethe University in Frankfurt, Germany. He received his PhD in Genetics from the Geisel School of Medicine at Dartmouth in the US and joined the Max Planck Institute for Molecular Genetics in Berlin, Germany, as postdoctoral fellow. His lab focuses on the function of lncRNA loci in early cardiovascular development with the focus on murine in vivo model systems.

Bio
Phillip Grote is principal investigator at the Institute of Cardiovascular Regeneration of the Goethe University in Frankfurt, Germany. He received his PhD in Genetics from the Geisel School of Medicine at Dartmouth in the US and joined the Max Planck Institute for Molecular Genetics in Berlin, Germany, as postdoctoral fellow. His lab focuses on the function of lncRNA loci in early cardiovascular development with the focus on murine in vivo model systems.

Dr. Chung Chau Hon

Team leader, Laboratory for Genome Information Analysis, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Japan

DETAILS

Dr Hon leads a team in RIKEN Japan, focusing on elucidating the function of non-coding genomic elements in genetic predisposition to diseases. He is particularly interested in the regulatory roles of non-coding transcriptions, e.g. enhancer RNAs and long non-coding RNAs, in control of gene expression under the context of diseases. His team uses a combination of bioinformatic, genetics and functional genomic approaches to identify and interrogate these disease relevant non-coding RNAs.

Bio
Dr Hon leads a team in RIKEN Japan, focusing on elucidating the function of non-coding genomic elements in genetic predisposition to diseases. He is particularly interested in the regulatory roles of non-coding transcriptions, e.g. enhancer RNAs and long non-coding RNAs, in control of gene expression under the context of diseases. His team uses a combination of bioinformatic, genetics and functional genomic approaches to identify and interrogate these disease relevant non-coding RNAs.

Dr. Reini Luco

Institute of Human Genetics (IGH-CNRS-UM) Website

DETAILS

Reini Luco did her PhD in Barcelona, working on the role of histone marks in nuclear organization. During her postdoc at NIH, she uncovered an unsuspected new role for histone modifications in driving the alternative splicing of co-regulated exons. As a group leader, she has delved deeper into the mechanisms of chromatin-mediated splicing regulation uncovering again an unsuspected new role for lncRNAs in inducing changes in alternative splicing via modulation of histone modifications.

Bio
Reini Luco did her PhD in Barcelona, working on the role of histone marks in nuclear organization. During her postdoc at NIH, she uncovered an unsuspected new role for histone modifications in driving the alternative splicing of co-regulated exons. As a group leader, she has delved deeper into the mechanisms of chromatin-mediated splicing regulation uncovering again an unsuspected new role for lncRNAs in inducing changes in alternative splicing via modulation of histone modifications.

Prof. Dr. Lina Ma

China National Center for Bioinformation / Beijing Institute of Genomics, Chinese Academy of Sciences, China Website

DETAILS

Dr. Lina Ma is an Associate Professor in National Genomics Data Center (NGDC) in China National Center for Bioinformation / Beijing Institute of Genomics, Chinese Academy of Sciences. Her major research interest is multi-omics annotation of human lncRNAs. As a Team Leader in NGDC, she is leading a team responsible for Non-coding RNA Resources that are devoted to lncRNA identification and curation based on big data integration and analytics.

Bio
Dr. Lina Ma is an Associate Professor in National Genomics Data Center (NGDC) in China National Center for Bioinformation / Beijing Institute of Genomics, Chinese Academy of Sciences. Her major research interest is multi-omics annotation of human lncRNAs. As a Team Leader in NGDC, she is leading a team responsible for Non-coding RNA Resources that are devoted to lncRNA identification and curation based on big data integration and analytics.

Prof. Dr. Eulàlia Martí

Department of Biomedical Sciences, University of Barcelona | Institut de Neurociències, University od Barcelona | Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Instituto Carlos III Website | Website | Twitter: @rna_neurodeg_UB

DETAILS

Eulàlia Martí received her Ph.D in Neurosciences (1996, University of Barcelona, Spain). She was postdoctoral researcher at the Centre de Genètica Mèdica i Molecular, Institut de Recerca Oncològica, (2001-2002) and Staff Scientist of the Genomics and Disease Group at the Centre for Genomic Regulation (2003-2015) where she was appointed as Group Leader of the Bioinformatics and Genomics Programme (2016-2017). Since 2018, she is associate professor and group leader at the Department of Biomedical Sciences, at the University of Barcelona,. Major highlights of her career are the discovery of ncRNA species with pathogenic potential early perturbed in the course of Parkinson’s disease, and the discovery of RNA-driven neurotoxicity as a novel pathogenic mechanism in Huntington’s disease.

Bio
Eulàlia Martí received her Ph.D in Neurosciences (1996, University of Barcelona, Spain). She was postdoctoral researcher at the Centre de Genètica Mèdica i Molecular, Institut de Recerca Oncològica, (2001-2002) and Staff Scientist of the Genomics and Disease Group at the Centre for Genomic Regulation (2003-2015) where she was appointed as Group Leader of the Bioinformatics and Genomics Programme (2016-2017). Since 2018, she is associate professor and group leader at the Department of Biomedical Sciences, at the University of Barcelona,. Major highlights of her career are the discovery of ncRNA species with pathogenic potential early perturbed in the course of Parkinson’s disease, and the discovery of RNA-driven neurotoxicity as a novel pathogenic mechanism in Huntington’s disease.

Prof. Dr. Pieter Mestdagh

Department of Biomolecular Medicine, Ghent University Cancer Research Institute Ghent Website

DETAILS

Pieter Mestdagh is a full professor at Ghent University and group leader at the Cancer Research Institute Ghent (CRIG). His lab is focused on studying the role of non-coding RNAs in cancer by combining functional genomics and applied bioinformatics approaches. The lab has a recognized expertise in gene expression data analysis and developed several research tools, databases and data analysis methods dedicated to the study of non-coding RNAs. Pieter Mestdagh is co-founder of various international consortia related to the study of ncRNAs including the miRNA Quality Control consortium (miRQC), the extracellular vesicles Quality Control study (evQC), the extracellular RNA Quality Control study (exRNAQC) and the RNA-Atlas consortium. Pieter Mestdagh authored more than 100 articles in international peer reviewed journals and is an inventor on several patents. Some of the tools he developed are licensed to commercial companies. His work has been awarded with various national prices and he was nominated among the top 5 young investigators in Belgium and the Netherlands by The New Scientist.

Bio
Pieter Mestdagh is a full professor at Ghent University and group leader at the Cancer Research Institute Ghent (CRIG). His lab is focused on studying the role of non-coding RNAs in cancer by combining functional genomics and applied bioinformatics approaches. The lab has a recognized expertise in gene expression data analysis and developed several research tools, databases and data analysis methods dedicated to the study of non-coding RNAs. Pieter Mestdagh is co-founder of various international consortia related to the study of ncRNAs including the miRNA Quality Control consortium (miRQC), the extracellular vesicles Quality Control study (evQC), the extracellular RNA Quality Control study (exRNAQC) and the RNA-Atlas consortium. Pieter Mestdagh authored more than 100 articles in international peer reviewed journals and is an inventor on several patents. Some of the tools he developed are licensed to commercial companies. His work has been awarded with various national prices and he was nominated among the top 5 young investigators in Belgium and the Netherlands by The New Scientist.

Dr. Samir Ounzain

Scientific Co-Founder and Chief Executive Officer HAYA Therapeutics SA

DETAILS

Samir Ounzain is a molecular biologist with over 15 years of experience exploring the dark matter of the transcriptome and its roles in cardiac development and disease. Prior to founding HAYA Therapeutics, Samir was a Project Leader and Research Fellow at the Lausanne University Hospital (CHUV), where his research efforts directly led to the discovery of hundreds of novel heart-enriched lncRNAs, most notably the lncRNA Wisper.

Bio
Samir Ounzain is a molecular biologist with over 15 years of experience exploring the dark matter of the transcriptome and its roles in cardiac development and disease. Prior to founding HAYA Therapeutics, Samir was a Project Leader and Research Fellow at the Lausanne University Hospital (CHUV), where his research efforts directly led to the discovery of hundreds of novel heart-enriched lncRNAs, most notably the lncRNA Wisper.

Dr. Yue Wan

Associate Director, Genome Institute of Singapore Website

DETAILS

Yue Wan received her B.Sc in Cell Biology and Biochemistry from the University of California, San Diego. She obtained her Ph.D in Cancer Biology from Stanford University, USA, under the mentorship of Howard Y. Chang. During her PhD, she developed the first high-throughput method for probing RNA structures genome-wide. Yue is a recipient of the NSS-PhD scholarship from Agency for Science, Technology and Research (A*STAR) in Singapore, and is currently a Associate director in the domain Epigenetics and Epitranscriptomics Regulation in the Genome Institute of Singapore. She is a Society in Science- Branco Weiss Fellow, EMBO Young Investigator and CIFAR-Azrieli Global Scholar. Yue is also a recipient of the Young Scientist Award and L’Oreal-UNESCO for Women in Science, Singapore National Fellowship. She is interested in studying functional RNA structures and understanding their roles in regulating cellular biology.

Bio
Yue Wan received her B.Sc in Cell Biology and Biochemistry from the University of California, San Diego. She obtained her Ph.D in Cancer Biology from Stanford University, USA, under the mentorship of Howard Y. Chang. During her PhD, she developed the first high-throughput method for probing RNA structures genome-wide. Yue is a recipient of the NSS-PhD scholarship from Agency for Science, Technology and Research (A*STAR) in Singapore, and is currently a Associate director in the domain Epigenetics and Epitranscriptomics Regulation in the Genome Institute of Singapore. She is a Society in Science- Branco Weiss Fellow, EMBO Young Investigator and CIFAR-Azrieli Global Scholar. Yue is also a recipient of the Young Scientist Award and L’Oreal-UNESCO for Women in Science, Singapore National Fellowship. She is interested in studying functional RNA structures and understanding their roles in regulating cellular biology.

Prof. Dr. Timofei Zatsepin

Associate Professor at the Center of Life Sciences, Skolkovo Institute of Science and Technology , Russia Website

DETAILS

Timofei Zatsepin is an Associate Professor at the Center of Life Sciences, Skolkovo Institute of Science and Technology (Moscow, Russia). He has received MS in Chemistry in 2000 and PhD degree in Bioorganic Chemistry Chemistry in 2003 from Moscow State University. Timofei is a strong scholar and entrepreneur awarded by Academia Europea Prize. His research interests are in oligonucleotides applications in vitro and in vivo, RNA biology and therapeutics with the focus on long noncoding RNA.

Bio
Timofei Zatsepin is an Associate Professor at the Center of Life Sciences, Skolkovo Institute of Science and Technology (Moscow, Russia). He has received MS in Chemistry in 2000 and PhD degree in Bioorganic Chemistry Chemistry in 2003 from Moscow State University. Timofei is a strong scholar and entrepreneur awarded by Academia Europea Prize. His research interests are in oligonucleotides applications in vitro and in vivo, RNA biology and therapeutics with the focus on long noncoding RNA.

Registration

The registration fee includes attendance to all conference sessions.

When registering as an "Academic", please register with your academic email address, as this will accelerate the registration process. If you are registering several people under the same registration, please do not use the same email address for each person, but their individual university email addresses. Thank you for your understanding.

Participation to the conference is considered final only once the registration fees have been paid. The number of participants is limited: once the number of paid registrations reaches the maximum number of participants, unpaid registrations will be cancelled.

Please note that, in order to finalize the scientific program in due time, at least one registration by any of the authors, denoted as Covering Author, is required to cover the presentation and publication of any accepted abstract. Covering Author registration deadline is 25 June 2021. Your abstract will be withdrawn if your registration is not complete by this date.

Regular Supported documents
Academic 100.00 CHF
Student 50.00 CHF Scanned copy or photograph of your current student ID is required
Members of Partnering Societies 80.00 CHF Society Membership Proof
Editorial Board Members of ncRNA 80.00 CHF
Non-Academic 150.00 CHF
Invited Speakers and MDPI Guests Free

Cancellation policy

Cancellation of paid registration is possible under the terms listed below:

> 2 weeks before the conference Full refund
< 2 weeks before the conference No refund

Disclaimer

We will endeavour to present the program advertised. However, MDPI and its partners reserve the right to alter or cancel, without prior notice, arrangements, timetables, plans, or other items relating directly or indirectly to Noncoding RNA World: From Mechanism to Therapy. MDPI and its partners are not liable for any loss or inconvenience caused as a result of such cancellation.

Beware of Unauthorized Registration

Note that Sciforum is the only official registration platform to register to ncRNA2021. Beware that entering into financial agreements with non-endorsed companies can have costly consequences.

Insurance

The organizers do not accept liability for personal accident, loss, or damage to private property incurred as a result of participation in Noncoding RNA World: From Mechanism to Therapy.

Photographs and/or video will be taken during the conference

By taking part in this event you grant the event organisers full rights to use the images resulting from the photography/video filming, and any reproductions or adaptations of the images for fundraising, publicity or other purposes to help achieve the conference’s aims. This might include (but is not limited to), the right to use them in their printed and online publicity, social media, press releases and funding applications.

Payment methods

Wire transfer, Credit card

Currencies accepted by this conference

US Dollar, Euro, Swiss franc


Instructions for Authors

Instructions

The conference "ncRNA2021 – Noncoding RNA World: From Mechanism to Therapy" will accept abstracts only.

The accepted abstracts will be available online on Sciforum.net during and after the conference.

Please note that abstract submission and conference registration are two separate processes.

To register for the conference, please follow this link.

To present your research at the event

  • Create an account on Sciforum if you do not have one, then click on ‘New Submission’ on the upper-right corner of the window, or by clicking on ‘Submit Abstract’ at the top of this webpage.
  • Indicate what thematic area is best suited for your research.
  • Submit an abstract in English - the word limits are minimum 150 words and maximum 300 words.
  • The deadline to submit your abstract is 26 March 2021. You will be notified by 30 April 2021 about the acceptance for poster presentation.
  • Upon submission, you can select if you wish to also be considered for oral presentation. Following assessment by the Chairs, you will be notified by 30 April 2021 in a separate email whether your contribution has been accepted for oral presentation.
  • Please note that, in order to finalize the scientific program in due time, at least one registration by any of the authors, denoted as Covering Author, is required to cover the presentation and publication of any accepted abstract. Covering Author registration deadline is 25 June 2021. Your abstract will be withdrawn if your registration is not complete by this date.
Oral Presentations

Short talks will be 15 min long including questions (12+3 Q&A). The typical presentation should be up to 10–12-minute talk.

All presentations must be sent to the conference secretariat in advance so that, in case you are encountering technical difficulties, we could share your slides to the audience.

Poster Information

Information about the poster session will be updated soon.

Publication Opportunities

All conference authors wishing to submit a full paper of their work to the journal ncRNA will receive a 50% discount on the Article Processing Charge. Please check the eligibility criteria below in order to benefit from the discount:

  • The author must have participated in the conference by submitting an abstract to the event.
  • Only authors of accepted abstracts will be eligible for the discount.
  • Authors must submit the full paper to the journal, or to any of its Special Issues*, before 1 November 2021.
  • Authors must submit in advance the tentative paper title and accepted abstract to [email protected] for application.

Please note that other institutional discounts cannot be combined with this discount voucher.

*The list of relevant Special Issues that are accepting submissions can be found here.

Preliminary Program

Below you will find the Preliminary Program for the ncRNA conference.

WEDNESDAY 21 JULY 2021

Session

Time in CEST

Time in CST Asia

Welcome from the Chairs

08:00-08:10

14:00-14:10

Keynote Speaker

08:10-09:00

14:10-15:00

BREAK

09:00-09:15

15:00-15:15

Mechanism of ncRNA processing and function

09:15-11:30

15:15-17:30

BREAK

11:30-12:00

17:30-18:00

Structure and bioinformatics of ncRNAS (Part 1)

12:00-13:00

18:00-19:00

BREAK

13:00-13:15

19:00-19:15

Posters

13:15-14:00

19:15-20:00

THURSDAY 22 JULY 2021

Session

Time in CEST

Time in CST Asia

Structure and bioinformatics of ncRNAS (Part 2)

08:00-09:00

14:00-15:00

BREAK

09:00-09:15

15:00-15:15

ncRNAs in development and diseases

09:15-11:30

15:15-17:30

BREAK

11:30-12:00

17:30-18:00

ncRNA therapeutics

12:00-14:15

18:00-20:15

BREAK

14:15-14:30

20:15-20:30

Posters

14:30-15:15

20:30-21:15

FRIDAY 23 JULY 2021

Session

Time in CEST

Time in CST Asia

Biotechnology of ncRNA

08:00-10:15

14:00-16:15

BREAK

10:15-10:30

16:15-16:30

Keynote Speaker

10:30-11:20

16:30-17:20

Closing of the Conference

11:20-11:30

17:20-17:30

Conference Awards

To acknowledge the support of the conference esteemed authors and recognize their outstanding scientific accomplishments, the non-coding RNA journal offers two awards: Best Oral Presentation and Best Poster. The nominations will be assessed by the Scientific Committee.

The Awards
Best Oral Presentation Award
CHF 500.-
Best Poster Award
CHF 400.-

Relevant Special Issues

If you wish to publish your research in the non-coding RNA journal, here is a list of Special Issues and Topical Collections that open for submission. Do not miss this chance to publish with MDPI!

Special Issues

The Importance of Non-coding RNAs in Epithelial Cancers
Submission Deadline: 31 July 2021
Guest edited by Leandro Castellano

Non-coding RNAs as Colorectal Cancer Biomarkers: Mechanisms of Action and Treatment Options
Submission Deadline: 31 July 2021
Guest edited by Barbara Pardini

Current Trends in MicroRNA Research: From Basics to Applications
Submission Deadline: 31 August 2021
Guest edited by Osamu Ishibashi

CRISPR/Cas Technology Applied to the Study of Non-coding RNAs in Cancer
Submission Deadline: 1 September 2021
Guest edited by Pier Paolo Pandolfi and Laura Poliseno

MicroRNAs in Aging and Neurodegenerative Diseases
Submission Deadline: 30 September 2021
Guest edited by André Fischer and Ivana Delalle

circRNAs in Cell and Organ Development
Submission Deadline: 20 September 2021
Guest edited by Kuei-Yang Hsiao

Non-coding RNA in Germany: Latest Advances and Perspectives
Submission Deadline: 30 September 2021
Guest edited by Tony Gutschner and Holger Bierhoff

Insights into Antisense Long Non-Coding RNAs Metabolism and Expression
Submission Deadline: 30 September 2021
Guest edited by Maxime Wery

Non-Coding RNAs Involved in Cancer Chemoresistance
Submission Deadline: 30 September 2021
Guest edited by Duncan Ayers and Ali Rihani

Secreted Non-coding RNAs as Signaling Molecules Driving Cell-to-Cell Communication in Cancer
Submission Deadline: 30 September 2021
Guest edited by Giulia Fontemaggi

Non-Coding RNAs and Cancer Genetics
Submission Deadline: 20 October 2021
Guest edited by Piotr Kozłowski

Regulation and Analysis of Noncoding RNA Sub- and Extra-Cellular Localization
Submission Deadline: 10 November 2021
Guest edited by Claire Rougeulle and Stéphan Vagner

Systematic Analysis of lncRNA Structures and Functions
Submission Deadline: 31 December 2021
Guest edited by Shizuka Uchida

Non-Coding RNAs and COVID-19
Submission Deadline: 31 March 2022
Guest edited by Gaetano Santulli and Jessica Gambardella

Topical Collections

Regulatory RNAs in Cardiovascular Development and Disease

Non-Coding RNA Methods

Non-Coding RNA Genes and Pseudogenes: Mechanisms of Formation and Transcript Properties
Guest edited by Nicholas Delihas

Feature Papers in Non-coding RNA
Guest edited by George A. Calin

Sponsors and Partners

We are happy to share with you our Sponsorship Agenda, and invite you and your company to participate in and sponsor our ncRNA2021 conference!

Information on sponsorship levels and the benefits can be found directly in the Agenda itself. If you have any questions or wish to discuss options further, please do not hesitate to contact the Conference Secretariat. We thank you for your consideration!

Organizers

Top